Trial Outcomes & Findings for Investigation of Low-intensity Focused Ultrasound Parameters (NCT NCT05134233)

NCT ID: NCT05134233

Last Updated: 2025-01-23

Results Overview

Changes in waveform peak will be observed per each variable application of LIFU

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

23 participants

Primary outcome timeframe

Outcome measured throughout study participation - an average of 4 weeks per participant.

Results posted on

2025-01-23

Participant Flow

Participant milestones

Participant milestones
Measure
Parameter Trials
Up to 15 parameter combinations will be tested per study session, expected up to 6 sessions of trials. Response recorded using TMS and EMG. Low-intensity Focused Ultrasound: LIFU application using various parameters, responses of neuromodulation recorded using TMS and EMG.
Overall Study
STARTED
23
Overall Study
COMPLETED
19
Overall Study
NOT COMPLETED
4

Reasons for withdrawal

Reasons for withdrawal
Measure
Parameter Trials
Up to 15 parameter combinations will be tested per study session, expected up to 6 sessions of trials. Response recorded using TMS and EMG. Low-intensity Focused Ultrasound: LIFU application using various parameters, responses of neuromodulation recorded using TMS and EMG.
Overall Study
Pregnancy
1
Overall Study
MEP value too low
2
Overall Study
Lost to Follow-up
1

Baseline Characteristics

Investigation of Low-intensity Focused Ultrasound Parameters

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Parameter Trials
n=23 Participants
Up to 15 parameter combinations will be tested per study session, expected up to 6 sessions of trials. Response recorded using TMS and EMG. Low-intensity Focused Ultrasound: LIFU application using various parameters, responses of neuromodulation recorded using TMS and EMG.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
23 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
Age, Continuous
29 years
n=5 Participants
Sex: Female, Male
Female
13 Participants
n=5 Participants
Sex: Female, Male
Male
10 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
21 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
8 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
2 Participants
n=5 Participants
Race (NIH/OMB)
White
13 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Region of Enrollment
United States
23 participants
n=5 Participants

PRIMARY outcome

Timeframe: Outcome measured throughout study participation - an average of 4 weeks per participant.

Population: One participant data set had artifacts that could not be removed while leaving usable MEP data.

Changes in waveform peak will be observed per each variable application of LIFU

Outcome measures

Outcome measures
Measure
Parameter Trials
n=18 Participants
Up to 15 parameter combinations will be tested per study session, expected up to 6 sessions of trials. Response recorded using TMS and EMG. Low-intensity Focused Ultrasound: LIFU application using various parameters, responses of neuromodulation recorded using TMS and EMG.
Waveforms
Parameter 19 (24W/cm2-50%DC-500msec)
0.93 percentage of baseline MEP mV
Standard Deviation 0.13
Waveforms
Parameter 1 (6W/cm2-1%DC-100msec)
1.06 percentage of baseline MEP mV
Standard Deviation 0.12
Waveforms
Parameter 2 (6W/cm2-10%DC-100msec)
1.10 percentage of baseline MEP mV
Standard Deviation 0.12
Waveforms
Parameter 3 (6W/cm2-30%DC-100msec)
0.97 percentage of baseline MEP mV
Standard Deviation .10
Waveforms
Parameter 4 (6W/cm2-50%DC-100msec)
0.99 percentage of baseline MEP mV
Standard Deviation 0.10
Waveforms
Parameter 5 (6W/cm2-70%DC-100msec)
1.03 percentage of baseline MEP mV
Standard Deviation 0.13
Waveforms
Parameter 6 (6W/cm2-1%DC-500msec)
0.80 percentage of baseline MEP mV
Standard Deviation 0.10
Waveforms
Parameter 7 (6W/cm2-10%DC-500msec)
0.84 percentage of baseline MEP mV
Standard Deviation 0.10
Waveforms
Parameter 8 (6W/cm2-30%DC-500msec)
0.70 percentage of baseline MEP mV
Standard Deviation 0.08
Waveforms
Parameter 9 (6W/cm2-50%DC-500msec)
0.81 percentage of baseline MEP mV
Standard Deviation 0.11
Waveforms
Parameter 10 (6W/cm2-70%DC-500msec)
0.75 percentage of baseline MEP mV
Standard Deviation 0.08
Waveforms
Parameter 11 (24W/cm2-1%DC-100msec)
0.86 percentage of baseline MEP mV
Standard Deviation 0.09
Waveforms
Parameter 12 (24W/cm2-10%DC-100msec)
0.93 percentage of baseline MEP mV
Standard Deviation 0.11
Waveforms
Parameter 13 (24W/cm2-30%DC-100msec)
1.01 percentage of baseline MEP mV
Standard Deviation 0.12
Waveforms
Parameter 14 (24W/cm2-50%DC-100msec)
0.91 percentage of baseline MEP mV
Standard Deviation 0.12
Waveforms
Parameter 15 (24W/cm2-70%DC-100msec)
0.91 percentage of baseline MEP mV
Standard Deviation 0.09
Waveforms
Parameter 16 (24W/cm2-1%DC-500msec)
0.75 percentage of baseline MEP mV
Standard Deviation 0.07
Waveforms
Parameter 17 (24W/cm2-10%DC-500msec)
0.79 percentage of baseline MEP mV
Standard Deviation 0.10
Waveforms
Parameter 18 (24W/cm2-30%DC-500msec)
0.84 percentage of baseline MEP mV
Standard Deviation 0.10
Waveforms
Parameter 20 (24W/cm2-70%DC-500msec)
0.84 percentage of baseline MEP mV
Standard Deviation 0.09
Waveforms
Parameter 21 (continuous- 6W/cm2-35000 cycles)
0.84 percentage of baseline MEP mV
Standard Deviation .11
Waveforms
Parameter 22 (continuous- 24W/cm2-35000 cycles)
1.05 percentage of baseline MEP mV
Standard Deviation 0.13
Waveforms
Parameter 23 (continuous- 6W/cm2-75000 cycles)
1.10 percentage of baseline MEP mV
Standard Deviation 0.13
Waveforms
Parameter 24 (continuous- 24W/cm2-75000 cycles)
0.99 percentage of baseline MEP mV
Standard Deviation 0.10

Adverse Events

Parameter Trials

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jessica Florig

Fralin Biomedical Research Institute at VTC

Phone: 540-526-2261

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place